Loading...
OTCM
DTZZF
Market cap13mUSD
Jul 09, Last price  
0.02USD
1D
3.71%
1Q
-10.38%
IPO
-84.97%
Name

Dotz Nano Ltd

Chart & Performance

D1W1MN
OTCM:DTZZF chart
P/E
P/S
61.82
EPS
Div Yield, %
Shrs. gr., 5y
13.36%
Rev. gr., 5y
-4.68%
Revenues
296k
0005,832,000112,012,000193,849,000205,701,000205,732,711182,731,00042,007,2470108,31815,39533,731375,811304,595191,90053,0250295,747
Net income
-9m
L+63.70%
-401,346-748,9531,635,338-90,261,000-31,446,0002,871,000-11,337,000-1,659,652-155,385,335-97,852,882-8,090,000-4,732,000-5,736,672-3,747,000-3,969,000-7,935,940-5,373,346-6,569,000-5,758,000-9,425,870
CFO
-2m
L-28.34%
-294,604-4,490,335-4,250,786-56,067,881018,739,00018,620,41910,315,739-20,674,565-1,932,417-3,399,384-4,445,682-2,667,384-2,447,667-4,157,684-4,809,534-4,614,448-3,114,416-2,231,899

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Dotz Nano Limited is dedicated to creating and commercializing advanced carbon-based materials that provide crucial solutions for tracing products, preventing counterfeiting, and addressing product liability. The company offers a suite of proprietary technologies, including ValiDotz, BioDotz, Fluorensic, and InSpec, which find application across numerous sectors. These range from enhancing brand security and safeguarding reputation to specialized uses in the oil and gas industry, tagging liquids, lubricants, and polymers, as well as in bio-imaging. Dotz Nano distributes its offerings globally, utilizing a network of partners in regions such as North America, Europe, Japan, China, and Australia. The company also fosters scientific alliances with various academic institutions and has a significant collaboration with Theracell Labs Ltd for the co-development, supply, and licensing of disposable bioprocessing consumables. Dotz Nano Limited's headquarters are located in Kfar Saba, Israel.
IPO date
Dec 13, 2007
Employees
350
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT